Cardiol Therapeutics Inc
CRDL
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx™, is a pharmaceutically produced extra strength oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in 422 COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.
Related content
As Health Problems Mount Patients Welcome New Treatments
Healthcare is changing, as more and more diseases pose a growing concern for society and the companies trying to cure them.
Tackling Recurring Health Conditions Offers Hope to Patients
Find out more about how Merck (NYSE: MRK), Bio-Techne Corporation (NASDAQ: TECH), Natera (NASDAQ: NTRA) and Cardiol Therapeutics (NASDAQ: CRDL)...
Cardiol Therapeutics Appoints Two New Directors To Its Board
Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Cardiol Therapeutics Announces FDA Investigational New Drug Application
Third IND authorization for CardiolRx™ in cardiovascular disease means this latest study will run in parallel with Company's multi-national Phase...
Cardiol's Heart Failure Treatment Offers Hope to Diabetics
We're discussing diabetes and heart failure with reference to Eli Lilly & Co. (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY) and...
Biotech stock Cardiol Therapeutics makes progress with clinical trial
Cardiol Therapeutics advances CardiolRx trial with its first Covid-19 positive patient. The CBD formulation may hold the key to reducing CVD...
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19
Cardiol Therapeutics announce that the first patient has been randomized in LANCER, a cannabidiol formulation being developed for chronic...
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™
Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options
Cardiol Therapeutics has submitted an application to uplist the Company’s common shares on The Nasdaq Capital Market® (the “Nasdaq”) and that it...
Pharma’s $7.2 Billion CBD Acquisition Could Trigger New Biotech Boom
How Cardiol Therapeutics Could Help Save the Most Vulnerable from Dying of COVID-19
Sign up for VTM Updates
VTM Exclusive Reports
Crypto Corner
Learn your NFTs from your BTCs